The current study found that stypoldione targets several deregulated genes in breast cancer, including ESR1, HSP90AA1, CXCL8, PTGS2, APP, MDM2, JAK2, KDR, LCK, GRM5, MAPK14, KIT, and signaling pathways such as VEGF pathway, PI3K-Akt pathway, FOXO signaling pathway, MAPK pathway, calcium signaling pathway and Neuroactive ligand-receptor interaction. This evidence concerns the gene APP and breast carcinoma.